KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short-term Investments (2016 - 2018)

Historic Short-term Investments for Travere Therapeutics (TVTX) over the last 6 years, with Q2 2018 value amounting to $166.4 million.

  • Travere Therapeutics' Short-term Investments fell 1951.23% to $166.4 million in Q2 2018 from the same period last year, while for Jun 2018 it was $166.4 million, marking a year-over-year decrease of 1951.23%. This contributed to the annual value of $201.2 million for FY2017, which is 634.57% down from last year.
  • Per Travere Therapeutics' latest filing, its Short-term Investments stood at $166.4 million for Q2 2018, which was down 1951.23% from $202.9 million recorded in Q1 2018.
  • In the past 5 years, Travere Therapeutics' Short-term Investments registered a high of $250.4 million during Q3 2016, and its lowest value of $5.9 million during Q2 2015.
  • Its 5-year average for Short-term Investments is $148.3 million, with a median of $199.7 million in 2016.
  • Per our database at Business Quant, Travere Therapeutics' Short-term Investments skyrocketed by 708528.66% in 2014 and then crashed by 1951.23% in 2018.
  • Travere Therapeutics' Short-term Investments (Quarter) stood at $9.6 million in 2014, then surged by 1907.11% to $191.8 million in 2015, then increased by 12.03% to $214.9 million in 2016, then fell by 6.35% to $201.2 million in 2017, then decreased by 17.32% to $166.4 million in 2018.
  • Its Short-term Investments was $166.4 million in Q2 2018, compared to $202.9 million in Q1 2018 and $201.2 million in Q4 2017.